Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic ...

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...

Praxis Precision Medicines (NASDAQ:PRAX) used its fourth-quarter and full-year 2025 earnings call to highlight multiple regulatory and clinical milestones across its central nervous system portfolio, ...

On Tuesday, Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic ...

Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in ...

Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec.

In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with ...